TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05379634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered intravenously in double-blind period and LTE period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nipocalimab matching placebo will be administered intravenously in double-blind period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Prednisone or equivalent will be administered orally as Glucocorticoid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucocorticoids
Description: Prednisone or equivalent will be administered orally as Glucocorticoid.
Study: NCT06107764

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittant theta burst stimulation (iTBS)
Description: iTBS consists of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous theta burst stimulation (cTBS)
Description: cTBS consists of 3 pulses at 50 Hz repeated at 5 Hz (every 200ms) continuously for a total of 600 pulses

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: sham rTMS does not deliver a significant change in magnetic field strength
Study: NCT05201794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802
Description: JNJ-64281802 tablets will be administered orally as per the defined regimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802
Description: JNJ-64281802 tablets will be administered orally as per the defined regimens.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for each dose level as tablet will be administered orally.
Study: NCT05720013

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice supplement
Description: The experimental arm includes orally ingesting 140 mL Beet-It Sport Nitrate 400.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: he placebo arm involves orally ingesting a 140 mL placebo solution with the dietary nitrate removed.
Study: NCT06319846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Initial infusion of tirofiban 0.4μg/kg body weight/minute for 30 minutes (a maximum dose of 1mg) within 24 hours of symptom onset, followed by a continuous infusion of tirofiban 0.1μg/kg body weight/minute for 48 hours.
Study: NCT06094868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib: 4mg, QD, PO, D1-D14, Q3W; Sintilimab: weight \< 60kg, 3mg/kg; weight≥60kg, 200 mg; I.V.， D1，Q3W；. XELOX regimen: Oxaliplatin: 130 mg/m2, ivgtt, D1, Q3W; Capecitabine: 1000 mg/m2, bid, D1-D14, Q3W; After 6 cycles of treatment, chemotherapy was given and maintenance treatment was given with Fruquintinib combined with Sintilimab. The above medication regimen can be adjusted according to the adverse reaction tolerance of the subjects.~\* Maintenance of treatment until disease progression, or intolerable toxic reactions, or other conditions determined by the investigator
Study: NCT06319846

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initial infusion of saline placebo for 30 minutes within 24 hours of symptom onset, followed by a continuous infusion of placebo for 48 hours.
Study: NCT05035836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given by PO
Study: NCT05155995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2001
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2001
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2001
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2001
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2007
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2007
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2007
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2007
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2008
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2008
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2008
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2008
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2102
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2102
Description: Take it once per period.
Study: NCT05117099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up
Description: This intervention includes access to the Family Check-Up Online website and telehealth coaching provided by trained mental health providers. A minimum of 5 coaching sessions will be offered.
Study: NCT05155995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2102
Description: Take it once per period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2102
Description: Take it once per period.
Study: NCT06349343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/BCMA CAR-T cell therapy
Description: CD19/BCMA CAR-T cell will be infused intravenously at 3 doses: Dose A, Dose B, Dose C.
Study: NCT06432036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angiogram
Description: Undergo angiogram

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioembolization
Description: Undergo radioembolization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Given intra-arterially
Study: NCT06559306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo tablets will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo tablets will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Description: SSRI/SNRI will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Description: SSRI/SNRI will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Description: SSRI/SNRI will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Description: SSRI/SNRI will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Description: SSRI/SNRI will be administered orally.
Study: NCT04720157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: administered intravenously once every 6 weeks (1 cycle) for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-PSMA-11
Description: Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARDT
Description: Administered orally on a continuous basis as per package insert and guideline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARDT
Description: Administered orally on a continuous basis as per package insert and guideline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: ADT are administered as per physician order

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: ADT are administered as per physician order
Study: NCT04360928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graymont X ERIS Knee Splint
Description: Specific type of splint which utilizes an inflatable air pocket on the posterior aspect of the leg to provide a combination of bracing and splinting in full extension in the immediate postoperative period.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Standard Hinge Knee Brace
Description: Standard knee brace used postoperatively after ACL reconstruction.
Study: NCT05191901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: Reducing pain and fear by squeezing a stress ball during the blood draw procedure.
Study: NCT06095102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT05856357

Intervention type: DRUG
Intervention: Sulfadoxine pyrimethamine
Description: Sulfadoxine-pyrimethamine paediatric formulation (250mg/12.5mg) dispersable tablets (Macleods Pharmaceuticals Ltd)
Study: NCT05318092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE
Description: The AngioDynamics' AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE has five main components, a flexible cannula (F1885), sheath, tapered obturator, aspirator handle, and waste bag.
Study: NCT06145698

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cross-frequency transcranial alternating current stimulation via the Neuroelectrics Starstim 32 transcranial electric stimulation device
Description: Stimulation will be delivered via the Neuroelectrics Starstim 32 transcranial electric stimulation device, an investigational electrical non-invasive brain stimulation device that is being used for clinical and translational research.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-frequency transcranial alternating current stimulation via the Neuroelectrics Starstim 32 transcranial electric stimulation device
Description: Stimulation will be delivered via the Neuroelectrics Starstim 32 transcranial electric stimulation device, an investigational electrical non-invasive brain stimulation device that is being used for clinical and translational research.
Study: NCT05747573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GB1211
Description: Hard tablet or capsules for oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GB1211
Description: Hard tablet or capsules for oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GB1211
Description: Hard tablet or capsules for oral use
Study: NCT05296044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT-003
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JT-003 Placebo
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT05793879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video 360
Description: Patients will undergo 12 sessions, 3 per weeks, 4 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard videos
Description: Patients will undergo 12 sessions, 3 per weeks, 4 weeks
Study: NCT05475990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch
Description: 10 ml/kg 6% Hydroxyethyl starch (130/0.4) coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid
Description: 10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT05528107

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lap IPOM plus
Description: Participants will undergo Lap IPOM plus repair according to the assigned treatment arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: eTEP
Description: Participants will undergo eTEP repair according to the assigned treatment arm.
Study: NCT04785820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomvastomig
Description: 2100 milligrams (mg) administered by intravenous (IV) infusion once every 2 weeks on Day 1 of each 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobemstomig
Description: 2100 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: 240 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.
Study: NCT06519513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes.
Study: NCT06581263

Intervention type: DEVICE
Intervention: Meta Quest 3
Description: Meta Quest 3 is a virtual reality headset device
Study: NCT04055207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VVC
Description: Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
Study: NCT05941442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darigabat
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT05218499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828)
Description: Brigimadlin (BI 907828)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828)
Description: Brigimadlin (BI 907828)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828)
Description: Brigimadlin (BI 907828)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: doxorubicin
Study: NCT05923073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered intravenously.
Study: NCT05655234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Breathing
Description: The MB programme consists of four stages: 1. Silent breathing for grounding (SB), 2. Music breathing for grounding (MBG), 3. Music breathing for modulation (MM), 4. Music breathing for working (MW).~After completing the silent breathing and music breathing practices, the participants will draw pictures of their body images of breathing space and centre. The form of the imagined breathing space expressed in the drawing and the meaning and content of the experience will be explored through a process facilitated by the therapist. The therapist's understanding of the participants' difficulties and progress will guide the next step, particularly the selection of music for the next sessions. The whole session takes about 2 hours. Weekly home practice is advised.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control condition
Description: The control condition consists of 30-min mental health education programme with topics on stress management, music playing, and breathing exercise provided in the first and 6th weeks. A take-home kit which consists of the fact sheet information of the health talk and the video link of the breathing exercise and musical pieces will be provided to the participants after the first meeting. They are instructed to practice the breathing exercise and listening to the musical pieces at home.
Study: NCT06386289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cereglide 92
Description: Aspiration of cerebral large vessels occlusions
Study: NCT06107738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide 1.0mg daily for days 1-21 of a 28-day cycle, an increase to 1.3 mg daily on Day 1-21 of a 28-day cycle is allowed at cycle 4 or higher if the 1.0 mg dose was well tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab/rHuPH20 Co-formulation
Description: Daratumumab/rHuPH20 will be dosed as follows:~* Daratumumab/rHuPH20 1800 mg SC days 1, 8, 15, 22 (28-day cycle; cycles 1-2)~* Daratumumab/rHuPH20 1800 mg SC days 1, 15 (28-day cycle; cycles 3-6)~* Daratumumab/rHuPH20 1800 mg SC day 1 (28-day cycle; cycles 7-26)
Study: NCT05372055

Intervention type: OTHER
Intervention: Semi-structure interviews
Description: Semi-structured interview focusing on psychosocial impact of living with an IPC to be performed at 2 weeks and 6-8 weeks post IPC insertion
Study: NCT03867487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Participants will take an identical appearing oral tablet with zero active ingredient.
Study: NCT06480591

Intervention type: OTHER
Intervention: Blood Draw
Description: The amount of blood that will be collected for this is 50 mL(milliliters), or about 3 ½ tablespoons.

Intervention type: OTHER
Intervention: Blood Draw
Description: The amount of blood that will be collected for this is 50 mL(milliliters), or about 3 ½ tablespoons.
Study: NCT05083169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally or intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered SC injection.
Study: NCT05936099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette & Tobacco Use Treatment Intervention
Description: The behavioral intervention includes health education on vaping health risk and outcomes, motivational interviewing, and assisted quit planning from a health educator and counseling and nicotine replacement therapy (if appropriate) provided by a physician.
Study: NCT05406817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Initial radiolabeled revumenib will be administered as an oral solution. Capsules will be administered thereafter.
Study: NCT05261399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: 300 mg savolitinib (3 × 100 mg tablets twice daily) Administrative route : oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80 mg osimertinib~(1 × 80 mg tablet once daily) Administrative route : oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed (500 mg/m2) Administrative route : IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (75 mg/m2) or Administrative route : IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (AUC5) Administrative route : IV infusion
Study: NCT05816395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHH646
Description: RHH646 capsule for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: RHH646 placebo capsule for oral use